Results 41 to 50 of about 491,575 (216)

Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer [PDF]

, 2011
International audienceDiffuse peritoneal dissemination in advanced ovarian cancer can be treated using optimal effort surgery involving peritonectomy procedures and the administration of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC)
Cascales Campos, Pedro Antonio, P. Parrilla Paricio, Gomez, Elena Gil, Martínez Frutos, Isabel María, Martinez, José Gil, Galindo Fernandez, Pedro J., Paricio, Pascual Parrilla, P.A. Cascales Campos, E. Gil Gómez, J. Gil Martínez, I.M. Martínez Frutos, P.J. Galindo Fernández   +11 more
core   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

Standardizing Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer Treatment: Navigating Complexities and Charting the Path Forward [PDF]

The incorporation of hyperthermic intraperitoneal chemotherapy (HIPEC) into the treatment landscape for ovarian cancer has invoked a spectrum of emotions, ranging from enthusiastic anticipation to cautious skepticism [...
Pedro Cascales-Campos, Juan José Segura-Sampedro, Segura-Sampedro, Juan José, Cascales-Campos, Pedro   +3 more
core   +1 more source

Hyperthermic intraperitoneal chemotherapy in colorectal cancer

BJS Open
Abstract Background This study evaluated the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer with peritoneal metastases (pmCRC) in a large international data set of patients. Patients and Methods
Rau, Beate, Gül-Klein, Safak
openaire   +5 more sources

Morbidity and Mortality of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients Aged 70 Years and Older: A Two‐Center 10‐Year Experience

Journal of Surgical Oncology, EarlyView.
ABSTRACT Background and Objectives Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is established for peritoneal surface malignancies, but its use in older patients is debated. We assessed CRS‐HIPEC morbidity and mortality in patients aged ≥ 70 years using a cohort of younger patients as a comparator.
Ali Ediz Kıvanç, Mehmet Oduncu, Pırıltı Özcan, Özgül Düzgün, Neşet Köksal   +4 more
wiley   +1 more source

Potential survival benefits from optimized chemotherapy implementation in advanced ovarian cancer: Projections from a microsimulation model.

PLoS ONE, 2019
BackgroundOvarian cancer is often diagnosed in advanced stages, when survival is poor. Treatment advances have been made, but are inconsistently implemented.
Anna P Lietz, Davis T Weaver, Alexander Melamed, Jose Alejandro Rauh-Hain, Jason D Wright, Alexi A Wright, Amy B Knudsen, Pari V Pandharipande   +7 more
doaj   +1 more source

Hyperthermic intraperitoneal chemotherapy: Rationale and technique

World Journal of Gastrointestinal Oncology, 2010
The combination of complete cytoreductive surgery and perioperative intraperitoneal chemotherapy provides the only chance for long-term survival for selected patients diagnosed with a variety of peritoneal neoplasms, either primary or secondary to digestive or gynecologic malignancy.
Santiago, González-Moreno, Luis A, González-Bayón, Gloria, Ortega-Pérez   +2 more
openaire   +2 more sources

Concentration‐Based Short‐Course Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at Interval Cytoreductive Surgery (iCRS) for Advanced Ovarian Cancer: Final Analysis of Overall Survival in a Phase 2 Trial

Journal of Surgical Oncology, EarlyView.
ABSTRACT Background The optimal regimen for Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) remains controversial. We aim to present long‐term overall survival results from our phase 2 trial evaluating a concentration‐based short‐course regimen for ovarian cancer at the time of interval CytoReductive Surgery (iCRS).
Thales Paulo Batista, Ana Beatriz Diniz de Barros, Vandré Cabral Gomes Carneiro, Rodrigo Tancredi, Levon Badiglian‐Filho, Ronaldo Lúcio Rangel Costa, André Lopes, Bruno José de Queiroz Sarmento, Cristiano Souza Leão   +8 more
wiley   +1 more source

Abdominal Wall Morbidity Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

, 2017
Background: Incisional hernia formation has been reported as high as 20% within 1 year following midline laparotomy. Since hyperthermic intraperitoneal chemotherapy is likely to impair wound healing, we sought to investigate the incidence of incisional ...
F. Struller, P. Horvath, I. Koenigsrainer, A. Koenigsrainer, S. Beckert   +4 more
core   +1 more source

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: Learning Curve Based on Surgical and Oncological Outcomes

, 2020
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a complex, highly specialized procedure used to treat peritoneal surface malignancies (PSM) [...
Wojciech P. Polkowski, Jerzy Mielko, Karol Rawicz-Pruszyński, Katarzyna Sędłak, Katarzyna Gęca, Magdalena Kwietniewska   +5 more
core   +1 more source